Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander J Ambinder

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Cancers|July 29, 2023
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading AwayYuya Nagai, Alexander J Ambinder
Haematologica|July 25, 2020
Potential targeting of FLT3 acute myeloid leukemiaAlexander J Ambinder, Mark Levis
Frontiers in Oncology|November 17, 2022
Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemiaAlexander J Ambinder, Amy E DeZern
Best Practice & Research. Clinical Haematology|May 29, 2020
Autoimmune disease in CMML-the chicken or the egg?Alexander J Ambinder, John Miller, Amy E DeZern
Cancer|January 24, 2013
Using primary site as a predictor of survival in mantle cell lymphomaAlexander J Ambinder, Pareen J Shenoy, Loretta J Nastoupil, et al.
Advances in Hematology|October 3, 2012
Exploring risk factors for follicular lymphomaAlexander J Ambinder, Pareen J Shenoy, Neha Malik, et al.
Transplantation and Cellular Therapy|March 23, 2024
Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant CyclophosphamideJonaphine Rae Mata, Marianna Zahurak, Natalie Rosen, et al.
Medrxiv : the Preprint Server for Health Sciences|September 4, 2023
Persistent <i>IDH</i> mutations are not associated with increased relapse or death in patients with <i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Frontiers in Oncology|November 16, 2020
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AMLAlexander J Ambinder, Kelly Norsworthy, Daniela Hernandez, et al.
Blood|April 12, 2015
Modified Ham test for atypical hemolytic uremic syndromeEleni Gavriilaki, Xuan Yuan, Zhaohui Ye, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Cancers|July 29, 2023
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading AwayYuya Nagai, Alexander J Ambinder
Haematologica|July 25, 2020
Potential targeting of FLT3 acute myeloid leukemiaAlexander J Ambinder, Mark Levis
Frontiers in Oncology|November 17, 2022
Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemiaAlexander J Ambinder, Amy E DeZern
Best Practice & Research. Clinical Haematology|May 29, 2020
Autoimmune disease in CMML-the chicken or the egg?Alexander J Ambinder, John Miller, Amy E DeZern
Cancer|January 24, 2013
Using primary site as a predictor of survival in mantle cell lymphomaAlexander J Ambinder, Pareen J Shenoy, Loretta J Nastoupil, et al.
Advances in Hematology|October 3, 2012
Exploring risk factors for follicular lymphomaAlexander J Ambinder, Pareen J Shenoy, Neha Malik, et al.
Transplantation and Cellular Therapy|March 23, 2024
Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant CyclophosphamideJonaphine Rae Mata, Marianna Zahurak, Natalie Rosen, et al.
Medrxiv : the Preprint Server for Health Sciences|September 4, 2023
Persistent <i>IDH</i> mutations are not associated with increased relapse or death in patients with <i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Frontiers in Oncology|November 16, 2020
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AMLAlexander J Ambinder, Kelly Norsworthy, Daniela Hernandez, et al.
Blood|April 12, 2015
Modified Ham test for atypical hemolytic uremic syndromeEleni Gavriilaki, Xuan Yuan, Zhaohui Ye, et al.
Pageof 2